Rani Therapeutics (RANI) grants CBO 805,500 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. reported that Chief Business Officer Kate McKinley received a grant of stock options covering 805,500 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.

According to the grant terms, one forty-eighth of the options vest monthly over four years starting April 1, 2026, as long as she maintains continuous service with the company. Following this award, she holds 805,500 stock options, aligning a portion of her compensation with the company’s future share performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McKinley Kate

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	805,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 805,500 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 805,500 options Exercise price: $0.875 per share Expiration date: June 2, 2036 +3 more

6 metrics

Stock options granted 805,500 options Grant to Chief Business Officer on June 3, 2026

Exercise price $0.875 per share Price to purchase Class A Common Stock under options

Expiration date June 2, 2036 Option term end date

Underlying shares 805,500 shares Class A Common Stock covered by the option grant

Post-grant option holdings 805,500 options Total derivative holdings following the transaction

Vesting schedule 1/48 monthly over 4 years From April 1, 2026, subject to continuous service

Key Terms

Stock Option (Right to Buy), Class A Common Stock, 2021 Equity Incentive Plan, Continuous Service, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

2021 Equity Incentive Plan financial

"as defined in the Company's 2021 Equity Incentive Plan"

Continuous Service financial

"subject to the Reporting Person's Continuous Service"

vest monthly financial

"1/48th of the shares subject to the option vest monthly"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 06:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKinley Kate

(Last)

(First)

(Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE

CALIFORNIA

95131

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.875	06/03/2026		A		805,500		⁽¹⁾	06/02/2036	Class A Common Stock	805,500	$0	805,500	D

Explanation of Responses:

1. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date.

	/s/ Svai Sanford, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Rani Therapeutics (RANI) disclose in this Form 4 for Kate McKinley?

Rani Therapeutics disclosed that Chief Business Officer Kate McKinley received a grant of 805,500 stock options. These options relate to Class A Common Stock and are part of her equity compensation package, aligning her interests with long-term shareholder value.

How many Rani Therapeutics stock options were granted to Kate McKinley?

Kate McKinley was granted 805,500 stock options for Rani Therapeutics Class A Common Stock. This entire amount represents her holdings after the transaction and reflects a significant component of her incentive-based compensation structure at the company.

What is the exercise price of Kate McKinley’s Rani Therapeutics options?

The exercise price of Kate McKinley’s stock options is $0.875 per share. This is the fixed price at which she can buy Rani Therapeutics Class A Common Stock once portions of the option grant have vested under the award terms.

When do Kate McKinley’s Rani Therapeutics stock options vest?

The options vest in equal monthly installments over four years starting April 1, 2026. Specifically, one forty-eighth of the total options vests each month, conditioned on her continued service with Rani Therapeutics throughout the vesting period.

When do Kate McKinley’s Rani Therapeutics options expire?

Kate McKinley’s stock options expire on June 2, 2036. After this expiration date, any unexercised vested options can no longer be used to purchase Rani Therapeutics Class A Common Stock under the grant’s specified terms.

Is this Rani Therapeutics Form 4 a market purchase or sale of shares?

This Form 4 reflects a grant of stock options, not a market purchase or sale. The transaction code is a grant or award, meaning she acquired derivative rights to buy shares in the future rather than trading existing stock in the open market.